SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2017
ONCOGENEX PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
033-80623
|
|
95-4343413
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
19820 North Creek Parkway
Bothell, Washington
|
|
98011
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants Telephone Number, Including Area Code: (425)
686-1500
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instructions A.2. below):
☒
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of
this chapter).
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
|
Results of Operations and Financial Condition.
|
On May 15, 2017, OncoGenex Pharmaceuticals, Inc.
(the Company) issued a press release announcing its financial results for the first quarter of 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release of OncoGenex Pharmaceuticals, Inc. dated May 15, 2017
|
The information in Item 2.02 of this Form
8-K
and Exhibit 99.1 attached hereto is furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ONCOGENEX PHARMACEUTICALS, INC.
|
|
|
|
|
Date: May 15, 2017
|
|
|
|
|
|
/s/ John Bencich
|
|
|
|
|
|
|
John Bencich
Chief Financial
Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release of OncoGenex Pharmaceuticals, Inc. dated May 15, 2017
|
Exhibit 99.1
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2017
BOTHELL, WA, and VANCOUVER, British Columbia, May
15, 2017
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced
financial results for the first quarter ended March 31, 2017.
Recent Events
|
|
|
In January 2017, Achieve Life Science, Inc. (Achieve) and OncoGenex announced they entered into a definitive merger agreement.
|
|
|
|
In February 2017, OncoGenex announced that apatorsen results from two randomized Phase 2 clinical trials were presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium,
held February 16
th
- 18
th
in Orlando. Clinical data from trials in bladder and prostate cancers demonstrated apatorsen was
well-tolerated and improved patient outcomes when administered in combination with
standard-of-care
treatments.
|
|
|
|
In March 2017, Achieve announced a strategic collaboration with the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) to conduct
non-clinical
studies in support of an overall clinical development plan for cytisine as a smoking cessation treatment. As part of the collaboration, Achieve is providing cytisine to the NIH to conduct a
series of
non-clinical
studies required by the U.S. Food and Drug Administration (FDA) to support the submission of an Investigational New Drug (IND) application. The collaboration commenced
in March 2015 and results of the studies are expected in the second-quarter of 2017.
|
|
|
|
In March 2017, the Society for Research in Nicotine and Tobacco (SRNT) held a symposium on cytisine research at its annual conference held in Florence, Italy. The symposium was chaired by
Professor Nancy Rigotti, MD, Massachusetts General Hospital/Harvard Medical School, with presentations from Associate Professor Natalie Walker, PhD, National Institute for Health Innovation, University of Auckland, on
Cytisine versus Varenicline for Smoking Cessation: Two Clinical Trials from the Australasian Cytisine Trialist Group, and The Challenge to Getting Cytisine Licensed For Use Worldwide: Policy
Considerations. Dr. Walker was the principal investigator of the 1,310 patient phase 3 CASCAID trial published in the New England Journal of Medicine in December, 2014 titled Cytisine versus Nicotine for Smoking
Cessation.
|
Financial Results
As
of March 31, 2017, the companys cash, cash equivalents, and short-term investments were $16.5 million compared with $25.5 million as of December 31, 2016. Based on current expectations, OncoGenex believes that its cash,
cash equivalents, and short-term investments will be sufficient to fund its currently planned operations for at least the next 12 months.
Revenue
for the three months ended March 31, 2017 decreased to zero from $2.9 million for three months ended March 31, 2016. Total operating expenses for the three months ended March 31, 2017 were $3.3
million compared to $7.4 million for the same period in 2016. Net loss for the three months ended March 31, 2017 was $3.3 million compared to $3.7 million for the same period in 2016.
As of May 15, 2017 OncoGenex had 30,087,485 shares outstanding.
About OncoGenex
OncoGenex is a biopharmaceutical company
committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. The companys product candidate, apatorsen
(OGX-427),
is designed to inhibit
production of Hsp27, disable cancer cells defenses and overcome treatment resistance. Hsp27 is an intracellular protein that protects cancer cells by helping them survive, leading to resistance and more aggressive cancer phenotypes. Both the
potential single-agent activity and synergistic activity of apatorsen with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.
More information is available at
www.OncoGenex.com
and at the companys Twitter account:
https://twitter.com/OncoGenex_IR.
About Achieve and Cytisine
Achieve is developing
cytisine as a smoking cessation aid. Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central
and Eastern Europe for more than 15 years. It is estimated that over 20 million people have used cytisine to help combat nicotine addiction, including approximately 2,000 patients in Phase 3 clinical trials conducted
in Europe and New Zealand. Achieves focus is to address the global smoking health epidemic, which is currently the leading cause of preventable death and is responsible for nearly six million people losing their lives annually
worldwide. Discussions have been held with FDA and a European regulatory agency to determine the clinical and regulatory pathway towards making cytisine widely available.
Important Additional Information about the Proposed Merger
This communication is being made in respect of the proposed merger involving OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. OncoGenex has filed
a registration statement on Form
S-4
(File
No. 333-216961)
with the Securities and Exchange Commission (SEC), which contains a preliminary proxy
statement/prospectus/information statement and other relevant materials, and plans to file with the SEC other documents regarding the proposed transaction. The final proxy statement/prospectus/information statement will be sent to the stockholders
of OncoGenex and Achieve. The proxy statement/prospectus/information statement contains information about OncoGenex, Achieve, the proposed merger and related matters. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS/INFORMATION
STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS) AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY AS THEY BECOME AVAILABLE, AS THEY CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT
THE MERGER AND RELATED MATTERS.
In addition to receiving the final proxy statement/prospectus/information statement and proxy card by mail, stockholders will also be able to obtain the proxy statement/prospectus/information statement, as well
as other filings containing information about OncoGenex, without charge, from the SECs website (http://www.sec.gov) or, without charge, by directing a written request to: OncoGenex Pharmaceuticals, Inc., 19820 North Creek
Parkway, Suite 201, Bothell, WA 98011, Attention: Investor Relations or to Achieve Life Science, Inc., 30 Sunnyside Avenue, Mill Valley, CA 94941, Attention: Rick Stewart.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in Solicitation
OncoGenex and its executive
officers and directors may be deemed to be participants in the solicitation of proxies from OncoGenexs stockholders with respect to the matters relating to the proposed merger. Achieve and its officers and directors may also be deemed a
participant in such solicitation. Information regarding OncoGenexs executive officers and directors is available in OncoGenexs proxy statement on Schedule 14A, filed with the SEC on April 21, 2016. Information regarding any interest
that OncoGenex, Achieve or any of the executive officers or directors of OncoGenex or Achieve may have in the transaction with Achieve will be set forth in the final proxy statement/prospectus/information statement that OncoGenex will file with the
SEC in connection with its stockholder vote on matters relating to the proposed merger. Stockholders will be able to obtain this information by reading the final proxy statement/prospectus/information statement when it becomes available.
OncoGenex Forward Looking Statements
This press
release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the proposed merger with Achieve
Life Science; the development of apatorsen and cytisine; the potential benefits of apatorsen and cytisine; and the adequacy of cash reserves. All statements other than statements of historical fact are statements that could be deemed
forward-looking statements. OncoGenex and/or Achieve may not actually achieve the proposed merger, or any plans or product development goals in a timely manner, if at all, or otherwise carry out the intentions or meet the expectations or projections
disclosed in these forward-looking statements. These statements are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially
from those described in the forward-looking statements, including, among others, the failure of the OncoGenex or Achieve stockholders to approve the transaction; the failure of either party to meet the closing conditions of the transaction; delays
in completing the transaction and the risk that the transaction may not be completed at all; the failure to realize the anticipated benefits from the transaction or delay in realization thereof; the success of the combined businesses; operating
costs and business disruption during the pendency of and following the proposed merger; the risk that product candidates will not receive regulatory approval or be successfully commercialized; the risk that new developments in the rapidly evolving
cancer therapy landscape require changes in business strategy or clinical development plans; the risk that product candidates may not demonstrate the hypothesized or expected benefits; general business and economic conditions; and the other factors
described in our risk factors set forth in OncoGenexs filings with the Securities and Exchange Commission from time to time, including its Annual Report on Form
10-K
and Quarterly Reports on
Form
10-Q.
OncoGenex undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by
applicable law.
OncoGenex Contact:
Hershel Berry
(415)
375-3340
ext. 1
hberry@bplifescience.com
Consolidated Statements of Loss
(In thousands, except per share and share data)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
|
Collaboration revenue
|
|
$
|
|
|
|
$
|
2,940
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
912
|
|
|
|
4,642
|
|
|
|
|
General and administrative
|
|
|
2,532
|
|
|
|
2,299
|
|
|
|
|
Restructuring costs (recovery)
|
|
|
(98
|
)
|
|
|
431
|
|
|
|
|
Litigation settlement loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
3,346
|
|
|
|
7,372
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(3,346
|
)
|
|
|
(4,432
|
)
|
|
|
|
Other income (expense)
|
|
|
77
|
|
|
|
725
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(3,269
|
)
|
|
$
|
(3,707
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(0.11
|
)
|
|
$
|
(0.12
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of basic and diluted common shares
|
|
|
30,076,160
|
|
|
|
29,827,824
|
|
|
|
|
|
|
|
|
|
|
Consolidated Balance Sheets
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
March 31,
2017
|
|
|
December 31,
2016
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents, short term investments and restricted cash
|
|
$
|
16,722
|
|
|
$
|
25,735
|
|
|
|
|
Interest receivable
|
|
|
|
|
|
|
32
|
|
|
|
|
Amounts receivable
|
|
|
237
|
|
|
|
478
|
|
|
|
|
Prepaid expenses and other current assets
|
|
|
765
|
|
|
|
954
|
|
|
|
|
Property, equipment and other assets
|
|
|
179
|
|
|
|
271
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
17,903
|
|
|
$
|
27,470
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity:
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$
|
1,745
|
|
|
$
|
8,166
|
|
|
|
|
Current portion of long-tem obligations
|
|
|
55
|
|
|
|
57
|
|
|
|
|
Warrant liability
|
|
|
180
|
|
|
|
232
|
|
|
|
|
Long term liabilities
|
|
|
32
|
|
|
|
49
|
|
|
|
|
Stockholders equity
|
|
|
15,891
|
|
|
|
18,966
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
17,903
|
|
|
$
|
27,470
|
|
|
|
|
|
|
|
|
|
|
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Mar 2023 to Mar 2024